An article from
Dive Brief
A strategic review determined that the development environment had “notably changed,” leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
Published June 11, 2026
Getty Images
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
426 words~2 min read
